Professor, Director Breast Cancer Prevention and Survivorship Centers
Oncology
Dr. Carol J. Fabian, MD
|
|
Give Review
Carol J. Fabian practices Oncology. He attended University of Kansas School of Medicine. He has 3 awards "America's Top Doctors", "America's Top Doctors for Cancer" and "Redbook Magazine: Top Breast Cancer Doctors". Carol Fabian is a published doctor as well. He has 36 publications published. The latest was: Incorporating Biomarkers in Studies of Chemoprevention. Carol J. Fabian, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeli...
- Omega-3 and Omega-6 Fatty Acids in Blood and Breast Tissue of High-Risk Women and Association with Atypical Cytomorphology.
- Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast Cancer.
- Germline BRCA mutation evaluation in a prospective triple-negative breast Cancer registry: implications for hereditary breast and/or ovarian Cancer syndrome testing.
- Protocol and recruitment results from a randomized controlled trial comparing group phone-based versus newsletter interventions for weight loss maintenance among rural...
- Cardiorespiratory fitness in breast Cancer survivors.
- Favorable modulation of benign Breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women.
- Simplifying the energy balance message for breast Cancer prevention.
- Outcomes of a weight loss intervention among rural breast Cancer survivors.
- Adiponectin: A Risk Biomarker and Attractive Target for Chemoprevention.
- Large prospective study of ovarian Cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
- Reduction in Ki-67 in benign Breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside.
- The relationship between vitamin D and breast Cancer incidence and natural history.
- How I treat vitamin d deficiency.
- Surrogate response biomarkers in prevention research: do they point the way or lead us astray?
- Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast Cancer previously treated with an anthracycline and a taxane.
- Tamoxifen prevents premalignant changes of breast, but not ovarian, Cancer in rats at high risk for both diseases.
- Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF.
- Low-dose tamoxifen for combination hormone replacement therapy users.
- Is there a future for ductal lavage?
- Karyometry of breast epithelial cells acquired by random periareolar fine needle aspiration in women at high risk for breast Cancer.
- Hypermethylation of the breast Cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast Cancer risk.
- Mammographic density: use in risk assessment and as a biomarker in prevention trials.
- Detection of biomarker gene expression by real-time polymerase chain reaction using amplified ribonucleic acids from formalin-fixed random periareolar fine needle aspi...
- Optimization of estrogen receptor analysis by immunocytochemistry in random periareolar fine-needle aspiration samples of Breast tissue processed as thin-layer prepara...
- Ki-67 expression in benign Breast ductal cells obtained by random periareolar fine needle aspiration.
- Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration.
- Selective estrogen-receptor modulators for primary prevention of breast Cancer.
- Ductal lavage for early detection--what doesn't come out in the wash.
- Breast Cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
- A phase II breast Cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
- Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
- Breast Cancer chemoprevention: current challenges and a look toward the future.
- Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
- Incorporating Biomarkers in Studies of Chemoprevention.
Schools
University of Kansas School of Medicine
Wesley Med Center
University Kans Med Center
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Redbook Magazine: Top Breast Cancer Doctors
Education
-
University of Kansas School of Medicine
Hospital
-
The University of Kansas Hospital
Drug Facts
| NPI NUMBER | 1215034780 | |
| NPPES Provider LastName | FABIAN | |
| NPPES Provider FirstName | CAROL | |
| NPPES Provider ZIPCode | 662052005 | |
| NPPES Provider State | KS | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 314.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1215034780 |
| Last Name Of The Provider | FABIAN |
| First Name Of The Provider | CAROL |
| View All |
Similar Doctors
|
|
Dr. Stephen K. Williamson, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Takefumi Komiya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joaquina C. Baranda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joaquina C. Baranda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prakash Neupane, MD
This Doctor is OpenDoctor Recommended.
|